| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Max Planck Institute for Infection Biology, Schumannstrasse 21/22, Campus Charité Mitte, 10117 Berlin, Germany
2 Institute of Virology, Philipps University Marburg, Robert-Koch-Strasse 17, 35037 Marburg, Germany
Correspondence
Thomas F. Meyer
meyer{at}mpiib-berlin.mpg.de
Stephan Becker
becker{at}staff.uni-marburg.de
High mortality rates and lack of an available vaccine against Marburg haemorrhagic fever (MHF) highlight the need for a defensive therapy against MHF and greater knowledge of the causative agent, the Marburg virus (MARV). Here, RNA interference (RNAi) is employed to destroy MARV transcripts, disrupting replication and allowing analysis of various roles of MARV proteins. Small interfering RNAs (siRNAs) homologous to three MARV transcripts (NP, VP35 and VP30) were co-transfected into cells with plasmids encoding the corresponding nucleocapsid proteins. The resulting decrease in MARV nucleocapsid-protein levels was shown to be specific, as siRNA that was not homologous to the MARV genome did not decrease the levels of viral nucleocapsid proteins. Additionally, transcript levels of double-stranded RNA (dsRNA)-sensor proteins, the dsRNA-activated protein kinase and 2',5'-oligoadenylate synthetase 1 remained unchanged, suggesting that the decrease in viral proteins was not a result of activation of the antiviral properties of the interferon system. Subsequently, siRNAs were shown to reduce intracellular viral proteins in MARV-infected cells and viral material released into the medium. Targeted reduction of VP30 downregulated the intracellular levels of all other viral proteins, suggesting that VP30 plays an essential role for transcription/replication. The efficient reduction of MARV replication also suggests that RNAi may provide an agent against MHF.
These authors made equal contributions to this work.
This article has been cited by other articles:
|
|
 |
|
  S. Enterlein, K. M. Schmidt, M. Schumann, D. Conrad, V. Krahling, J. Olejnik, and E. Muhlberger The Marburg Virus 3' Noncoding Region Structurally and Functionally Differs from That of Ebola Virus J. Virol., May 1, 2009; 83(9): 4508 - 4519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Enterlein, K. L. Warfield, D. L. Swenson, D. A. Stein, J. L. Smith, C. S. Gamble, A. D. Kroeker, P. L. Iversen, S. Bavari, and E. Muhlberger VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice Antimicrob. Agents Chemother., March 1, 2006; 50(3): 984 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Enterlein, V. Volchkov, M. Weik, L. Kolesnikova, V. Volchkova, H.-D. Klenk, and E. Muhlberger Rescue of Recombinant Marburg Virus from cDNA Is Dependent on Nucleocapsid Protein VP30 J. Virol., January 15, 2006; 80(2): 1038 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Moller, N. Pariente, H.-D. Klenk, and S. Becker Homo-Oligomerization of Marburgvirus VP35 Is Essential for Its Function in Replication and Transcription J. Virol., December 1, 2005; 79(23): 14876 - 14886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bamberg, L. Kolesnikova, P. Moller, H.-D. Klenk, and S. Becker VP24 of Marburg Virus Influences Formation of Infectious Particles J. Virol., November 1, 2005; 79(21): 13421 - 13433. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
